Recent PET radioligands with optimal brain kinetics for imaging nicotinic acetylcholine receptors.

Cerebral neuronal nicotinic acetylcholine receptors (nAChRs) are implicated in various neurophysiological processes and in the pathophysiology and/or treatment strategies of various disorders. Positron emission tomography (PET) imaging of nAChR and, especially, the most prominent cerebral subtype α4β2-nAChR is important in smoking, epilepsy, attention deficit hyperactivity disorder, depression, schizophrenia, cognition, behavior, memory, and in research involving aging, cognitive impairments, and dementia. Most human α4β2-nAChR PET imaging has been performed with 2-[(18) F]FA, but slow brain kinetics is the substantial drawback of 2-[(18) F]FA that precludes widespread PET imaging research of nAChR in humans. Development of a better PET radioligand for α4β2-nAChR was a focus of substantial investigation that has been thoroughly reviewed (up to 2009) previously. This article attempts to summarize the peer-reviewed publications of the most recent development and preclinical studies of novel α4β2-nAChR PET radioligands with improved brain kinetics and first human studies with one of these radioligands ([(18) F]AZAN).

[1]  L. Eriksson,et al.  PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo , 1994, Psychopharmacology.

[2]  Hiroto Kuwabara,et al.  Discovery of (-)-7-methyl-2-exo-[3'-(6-[18F]fluoropyridin-2-yl)-5'-pyridinyl]-7-azabicyclo[2.2.1]heptane, a radiolabeled antagonist for cerebral nicotinic acetylcholine receptor (alpha4beta2-nAChR) with optimal positron emission tomography imaging properties. , 2008, Journal of medicinal chemistry.

[3]  M. Patt,et al.  Norchloro-fluoro-homoepibatidine (NCFHEB) — A promising radioligand for neuroimaging nicotinic acetylcholine receptors with PET , 2008, European Neuropsychopharmacology.

[4]  Elliot A Stein,et al.  Greater Nicotinic Acetylcholine Receptor Density in Smokers Than in Nonsmokers: A PET Study with 2-18F-FA-85380 , 2008, Journal of Nuclear Medicine.

[5]  Marianne Patt,et al.  In vivo measurement of nicotinic acetylcholine receptors with [18F]norchloro‐fluoro‐homoepibatidine , 2008, Synapse.

[6]  Swen Hesse,et al.  Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer’s disease assessed with positron emission tomography , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  G. Savage,et al.  Relationship between nicotinic receptors and cognitive function in early Alzheimer’s disease: A 2-[18F]fluoro-A-85380 PET study , 2008, Neurobiology of Learning and Memory.

[8]  Mary L. Schneider,et al.  PET Imaging of α4β2* Nicotinic Acetylcholine Receptors: Quantitative Analysis of 18F-Nifene Kinetics in the Nonhuman Primate , 2012, The Journal of Nuclear Medicine.

[9]  P. Brust,et al.  Development of radioligands for the imaging of α7 nicotinic acetylcholine receptors with positron emission tomography. , 2012, Current drug targets.

[10]  M. Berridge,et al.  Teflon radiolysis as the major source of carrier in fluorine-18 , 2009 .

[11]  J K Lynch,et al.  Neuronal nicotinic acetylcholine receptors as targets for drug discovery. , 1997, Journal of medicinal chemistry.

[12]  P. Brust,et al.  Molecular Imaging of 7 Nicotinic Acetylcholine Receptors In Vivo: Current Status and Perspectives , 2012 .

[13]  Yu-Shin Ding,et al.  Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer’s dementia , 2001, Biological Psychiatry.

[14]  B. Christian,et al.  Nicotinic α4β2 receptor imaging agents. Part III. Synthesis and biological evaluation of 3-(2-(S)-azetidinylmethoxy)-5-(3'-18F-fluoropropyl)pyridine (18F-nifzetidine). , 2011, Nuclear medicine and biology.

[15]  D. Comar,et al.  Nicotine-11C: Synthesis and distribution kinetics in animals , 1976, European Journal of Nuclear Medicine.

[16]  K. Hashimoto,et al.  Recent development of radioligands for imaging α7 nicotinic acetylcholine receptors in the brain. , 2010, Current topics in medicinal chemistry.

[17]  C. Gotti,et al.  Human neuronal nicotinic receptors , 1997, Progress in Neurobiology.

[18]  Abass Alavi,et al.  Planar and SPECT imaging in the era of PET and PET–CT: can it survive the test of time? , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  A. Nordberg,et al.  Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain , 2000, Acta neurologica Scandinavica. Supplementum.

[20]  S. Potkin,et al.  Nicotinic alpha4beta2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate. , 2006, Nuclear medicine and biology.

[21]  Renaud Maroy,et al.  Minimally invasive input function for 2-18F-fluoro-A-85380 brain PET studies , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  C Crouzel,et al.  Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors. , 1999, Journal of medicinal chemistry.

[23]  Svetlana I. Chefer,et al.  Cigarette Smoking Saturates Brain α4β2 Nicotinic Acetylcholine Receptors , 2006 .

[24]  T. Nayak,et al.  In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers , 2011, EJNMMI research.

[25]  Habib Zaidi,et al.  PET versus SPECT: strengths, limitations and challenges , 2008, Nuclear medicine communications.

[26]  M. Mandelkern,et al.  A Single Administration of Low-Dose Varenicline Saturates α4β2* Nicotinic Acetylcholine Receptors in the Human Brain , 2012, Neuropsychopharmacology.

[27]  J P Changeux,et al.  International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. , 1999, Pharmacological reviews.

[28]  Yun Zhou,et al.  Positron emission tomography experience with 2‐[18F]fluoro‐3‐(2(s)‐azetidinylmethoxy)pyridine (2‐[18F]fa) in the living human brain of smokers with paranoid schizophrenia , 2012, Synapse.

[29]  Hiroto Kuwabara,et al.  Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. , 2010, Life sciences.

[30]  Agneta Nordberg,et al.  Neuronal nicotinic receptors in the human brain , 2000, Progress in Neurobiology.

[31]  Christopher C Rowe,et al.  Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET. , 2005, Nuclear medicine and biology.

[32]  D Wyper,et al.  Nicotinic Acetylcholine Receptor Distribution in Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease, and Vascular Dementia: In Vitro Binding Study Using 5-[125I]-A-85380 , 2004, Neuropsychopharmacology.

[33]  S. Potkin,et al.  Synthesis and Evaluation of Nicotine 42 Receptor Radioligand, 5-(3- 18 F-Fluoropropyl)-3- (2-(S)-Pyrrolidinylmethoxy)Pyridine, in Rodents and PET in Nonhuman Primate , 2005 .

[34]  Dean F. Wong,et al.  PET Imaging of Nicotinic Acetylcholine Receptors in Baboons with 18F-AZAN, a Radioligand with Improved Brain Kinetics , 2012, The Journal of Nuclear Medicine.

[35]  B. Christian,et al.  Specific α4β2 nicotinic acetylcholine receptor binding of [F‐18]nifene in the rhesus monkey , 2011, Synapse.

[36]  E. Sher,et al.  Sazetidine-A Is a Potent and Selective Agonist at Native and Recombinant α4β2 Nicotinic Acetylcholine Receptors , 2008, Molecular Pharmacology.

[37]  D. Wong,et al.  Clinical Perspective and Recent Development of PET Radioligands for Imaging Cerebral Nicotinic Acetylcholine Receptors. , 2009, PET clinics.

[38]  Elliot A. Stein,et al.  Quantification of nicotinic acetylcholine receptors in the human brain with PET: Bolus plus infusion administration of 2-[18F]F-A85380 , 2008, NeuroImage.

[39]  Victor L Villemagne,et al.  The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. , 2006, Current pharmaceutical design.

[40]  A. Hufnagel,et al.  Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study. , 2006, Brain : a journal of neurology.

[41]  P. Parekh,et al.  Evaluation of 18F-nifene binding to α4β2 nicotinic receptors in the rat brain using microPET imaging , 2011, EJNMMI research.

[42]  S. Granon,et al.  [18F]ZW‐104, a new radioligand for imaging α2‐α3‐α4/β2 central nicotinic acetylcholine receptors: Evaluation in mutant mice , 2010, Synapse.

[43]  M. Kassiou,et al.  18F-ZW-104: A New Radioligand for Imaging Neuronal Nicotinic Acetylcholine Receptors—In Vitro Binding Properties and PET Studies in Baboons , 2009, Journal of Nuclear Medicine.

[44]  D. Gündisch,et al.  Nicotinic acetylcholine receptors and imaging. , 2000, Current pharmaceutical design.

[45]  Osama Sabri,et al.  Acetylcholine receptors in dementia and mild cognitive impairment , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[46]  Y. Yonekura,et al.  Synthesis of (S)-N-[methyl-11C]nicotine and its regional distribution in the mouse brain: a potential tracer for visualization of brain nicotinic receptors by positron emission tomography. , 1992, Chemical & pharmaceutical bulletin.

[47]  Edythe D London,et al.  Graphical analysis of 2‐[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain , 2003, Synapse.

[48]  F. Mottaghy,et al.  Feasibility of [18F]-2-Fluoro-A85380-PET imaging of human vascular nicotinic acetylcholine receptors in vivo. , 2012, JACC. Cardiovascular imaging.

[49]  C. Gotti,et al.  Brain neuronal nicotinic receptors as new targets for drug discovery. , 2006, Current pharmaceutical design.

[50]  A. Horti,et al.  Synthesis and evaluation of a novel series of 2-chloro-5-((1-methyl-2-(S)-pyrrolidinyl)methoxy)-3-(2-(4-pyridinyl)vinyl)pyridine analogues as potential positron emission tomography imaging agents for nicotinic acetylcholine receptors. , 2002, Journal of medicinal chemistry.

[51]  John L. Musachio,et al.  Synthesis of a radiotracer for studying nicotinic acetylcholine receptors: 2-[18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[18F]A-85380) , 1998 .

[52]  C. Crouzel,et al.  Synthesis of 2‐[18F]fluoro‐3‐[2(S)‐2‐azetidinylmethoxy]pyridine, a highly potent radioligand for in vivo imaging central nicotinic acetylcholine receptors , 1998 .

[53]  A. Nordberg,et al.  Development of ligands for in vivo imaging of cerebral nicotinic receptors , 2000, Behavioural Brain Research.

[54]  Yu-Shin Ding,et al.  New-generation radiotracers for nAChR and NET. , 2005, Nuclear medicine and biology.

[55]  N. Weinberger,et al.  Nicotinic acetylcholine receptors in rat forebrain that bind 18F‐nifene: Relating PET imaging, autoradiography, and behavior , 2012, Synapse.